Old Web
English
Sign In
Acemap
>
authorDetail
>
Michiel W. van den Heuvel
Michiel W. van den Heuvel
Merck & Co.
Anesthesia
Medicine
Pharmacokinetics
Population
Rocuronium
4
Papers
96
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Development of In Vitro–In Vivo Correlation for Extended‐Release Niacin After Administration of Hypromellose‐Based Matrix Formulations to Healthy Volunteers
2014
Journal of Pharmaceutical Sciences
Filippos Kesisoglou
Stefaan Rossenu
Colm Farrell
Michiel W. van den Heuvel
Marita Prohn
Shaun Fitzpatrick
Pieter-Jan de Kam
Ryan C. Vargo
Show All
Source
Cite
Save
Citations (12)
Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study
2012
Clinical Drug Investigation
Peter G. Schnabel
Gabriele S. Merki-Feld
Alice Malvy
Ingrid Duijkers
Ellen Mommers
Michiel W. van den Heuvel
Show All
Source
Cite
Save
Citations (7)
Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.
2011
British Journal of Clinical Pharmacology
Huub-Jan Kleijn
Daniel P. Zollinger
Michiel W. van den Heuvel
Thomas Kerbusch
Show All
Source
Cite
Save
Citations (24)
Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study.
2010
Clinical Drug Investigation
Pierre A. M. Peeters
Michiel W. van den Heuvel
Emiel van Heumen
Paul C. C. M. Passier
Jean Smeets
Thijs van Iersel
Alex Zwiers
Show All
Source
Cite
Save
Citations (53)
1